Chanca Piedra (Phyllanthus niruri) for Kidney Stones: Efficacy and Safety
Chanca piedra supplements show modest efficacy in reducing kidney stone burden and preventing recurrence, with an excellent safety profile and no significant adverse effects reported in clinical studies.
Efficacy Evidence
Stone Reduction and Clearance
The clinical evidence, while limited in quantity, demonstrates consistent benefits:
Meta-analysis findings 1: Chanca piedra treatment resulted in significant decreases in mean stone size (standardized mean difference -0.39 cm, p = 0.01) and stone number (standardized mean difference -0.38, p = 0.01).
Post-ESWL outcomes 2: When used as adjuvant therapy after extracorporeal shock wave lithotripsy, chanca piedra achieved a 93.5% stone-free rate versus 83.3% in controls at 180 days. For lower calyceal stones specifically, the stone-free rate was 93.7% versus 70.8% in controls (p = 0.01), representing the strongest evidence for clinical benefit.
Stone elimination 3: In a 12-week prospective study, kidney stones decreased from 3.2±2 to 2.0±2 per patient (p<0.001).
Metabolic Effects
Chanca piedra demonstrates targeted metabolic benefits in specific patient populations 3, 4:
- In hyperoxaluric patients: Urinary oxalate reduced from 59.0±11.7 to 28.8±16.0 mg/24-hour (p=0.0002)
- In hyperuricosuric patients: Urinary uric acid decreased from 0.77±0.22 to 0.54±0.07 mg/24-hour (p=0.0057)
- In hypercalciuric patients: Mean urinary calcium reduced from 4.8±1.0 to 3.4±1.1 mg/kg/24-hour (p<0.05) 4
- Increased urinary magnesium and potassium excretion, both protective factors against stone formation
Safety Profile
The safety data is remarkably consistent across all studies, showing chanca piedra to be exceptionally well-tolerated:
- No genotoxicity or cytotoxicity demonstrated in laboratory studies 5
- No hepato-renal toxicity after 90-day subchronic administration 5
- No significant adverse effects on serum metabolic parameters, including total blood count, creatinine, uric acid, electrolytes, or liver function 3
- Adverse effect rates of only 3.9-4.5% across multiple platforms of patient-reported outcomes 6
- No severe adverse effects reported in clinical trials 2, 3
This safety profile is particularly notable when compared to conventional pharmacologic therapies for nephrolithiasis, which carry risks of electrolyte disturbances (thiazides), gastrointestinal effects (citrates), and various drug-specific toxicities 7.
Clinical Context and Positioning
Comparison to Guideline-Recommended Therapies
The American College of Physicians guidelines 7 recommend:
- First-line: Increased fluid intake to achieve ≥2L urine output daily
- Second-line: Pharmacologic monotherapy with thiazide diuretics, citrate, or allopurinol when fluid intake fails
Chanca piedra occupies a unique position: While not included in formal guidelines (likely due to limited high-quality RCT data), its efficacy appears comparable to conventional agents for specific indications, particularly as adjuvant therapy post-ESWL and in patients with metabolic abnormalities like hypercalciuria, hyperoxaluria, or hyperuricosuria.
Optimal Use Strategy
Based on the evidence, chanca piedra is most appropriately used:
As adjuvant therapy following ESWL, especially for lower pole stones, where it significantly improves stone-free rates 2
In patients with documented metabolic abnormalities (hypercalciuria, hyperoxaluria, hyperuricosuria) who may benefit from its targeted effects on urinary chemistry 3, 4
As a complementary approach alongside conventional dietary modifications (adequate hydration, normal calcium intake, reduced sodium and animal protein) 8, 7
Typical dosing: 450 mg capsules three times daily or 2 grams daily, administered for at least 3 months 2, 4
Important Caveats and Limitations
Evidence Quality
- Only two studies met inclusion criteria for the systematic review meta-analysis 1, indicating limited high-quality RCT data
- Most studies are small, single-center trials
- Longer-term outcomes beyond 6 months are not well-established
- No head-to-head comparisons with guideline-recommended pharmacologic therapies exist
Regulatory Considerations
As a dietary supplement 9, 10:
- Not FDA-approved for kidney stone treatment
- Subject to less stringent manufacturing standards than pharmaceuticals
- Quality and purity may vary between products
- Should be discontinued 1-2 weeks before surgery per perioperative guidelines 10
Patient Selection
While generally safe, consider:
- Patients should maintain adequate dietary calcium intake (not restrict it) per established guidelines 8, 11
- Those with suspected hyperparathyroidism or rare stone types require different management 7
- Metabolic evaluation (24-hour urine collection) helps identify patients most likely to benefit 7
Growing Public Interest
Google Trends analysis 1 shows public interest in chanca piedra now exceeds that of ESWL and PCNL, reflecting rising demand that may outpace the clinical evidence base—emphasizing the need for informed counseling.
Practical Recommendation Algorithm
For patients with recurrent calcium oxalate stones:
Implement guideline-based dietary modifications first: Increase fluid intake to achieve ≥2L urine output, maintain normal dietary calcium (1000-1200 mg/day), reduce sodium and animal protein 7
Consider 24-hour urine metabolic evaluation to identify specific abnormalities 7
If stones persist despite dietary measures:
- Post-ESWL patients, especially with lower pole stones: Add chanca piedra 450 mg TID for 3-6 months 2
- Patients with hypercalciuria, hyperoxaluria, or hyperuricosuria: Consider chanca piedra 2g daily for 3 months, with repeat metabolic evaluation 3, 4
- Patients preferring conventional therapy or with contraindications to supplements: Use thiazide diuretics, citrate, or allopurinol per ACP guidelines 7
Monitor response with imaging and metabolic parameters at 3-6 months
Ensure product quality by selecting supplements from reputable manufacturers following Good Manufacturing Practices 9